Stock Events

Stock Events

Jasper Therapeutics 

$0.02
27
+$0+0% Tuesday 17:30

Statistics

Day High
0.02
Day Low
0.02
52W High
0.02
52W Low
0.02
Volume
1,140
Avg. Volume
-
Mkt Cap
612,849.6
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.74
-1.4
-1.06
-0.72
Expected EPS
-0.7246
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-142.54MNet Income

Analyst Ratings

$4.17Average Price Target
The highest estimate is 7.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JSPRW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the innovative therapy space including treatments for cancer and genetic diseases, similar to Jasper's focus on hematologic cancers and gene therapies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, a direct competitor to Jasper's work in hematologic malignancies and cell therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for cancer, overlapping with Jasper's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis is a major player in gene and cell therapy, including Kymriah for cancer treatment, competing in the same therapeutic areas as Jasper.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic medicine, including gene therapy, gene editing, and cell therapy, areas of direct competition with Jasper.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, competing with Jasper in the broader gene therapy market.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies is involved in immune-driven medicine, including cancer, which competes with Jasper's focus on hematologic malignancies and immune therapies.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is developing programmed cellular immunotherapies for cancer and immune disorders, directly competing with Jasper's cell therapy approaches.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is involved in various therapeutic areas including oncology and gene therapy, making it a competitor in the broader market that Jasper operates in.

About

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Show more...
CEO
Mr. Ronald A. Martell
Employees
64
Country
US
ISIN
US4718711116

Listings

XNAS
US
JSPRW
XNAS
US
JSPR
BOATS
BOATS
JSPR.BOATS

0 Comments

Share your thoughts

FAQ

What is Jasper Therapeutics stock price today?▼
The current price of JSPRW is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Jasper Therapeutics stock price performance more closely on the chart.
What is Jasper Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Jasper Therapeutics stocks are traded under the ticker JSPRW.
Is Jasper Therapeutics stock price growing?▼
JSPRW stock has fallen by -0.9% compared to the previous week, the month change is a +15.87% rise, over the last year Jasper Therapeutics has showed a -83.15% decrease.
What is Jasper Therapeutics market cap?▼
Today Jasper Therapeutics has the market capitalization of 612,849.6
When is the next Jasper Therapeutics earnings date?▼
Jasper Therapeutics is going to release the next earnings report on May 08, 2026.
What were Jasper Therapeutics earnings last quarter?▼
JSPRW earnings for the last quarter are -1.13 USD per share, whereas the estimation was -1.21 USD resulting in a +6.99% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Jasper Therapeutics revenue for the last year?▼
Jasper Therapeutics revenue for the last year amounts to 0 USD.
What is Jasper Therapeutics net income for the last year?▼
JSPRW net income for the last year is -142.54M USD.
How many employees does Jasper Therapeutics have?▼
As of April 03, 2026, the company has 64 employees.
In which sector is Jasper Therapeutics located?▼
Jasper Therapeutics operates in the Health Care sector.
When did Jasper Therapeutics complete a stock split?▼
The last stock split for Jasper Therapeutics was on January 04, 2024 with a ratio of 1:10.
Where is Jasper Therapeutics headquartered?▼
Jasper Therapeutics is headquartered in Redwood City, US.